PharmaCyte Biotech, Inc. (PMCB) · Oct 16, 2026 · Auditor change
Auditor change — CBIZ replaced by Grassi; no disagreements reported
PharmaCyte changed auditors for fiscal 2027, reporting no accounting dispute—but material weaknesses in financial controls remain the key signal.
PharmaCyte remains an early-stage biotech trying to advance its Cell-in-a-Box cancer-therapy platform toward a pancreatic-cancer trial, with no approved products or revenue and an FDA clinical hold that has remained unresolved since 2020. Against that backdrop, this filing is administrative rather than a clinical or financing catalyst.
The auditor switch does not indicate a reported accounting fight. The Audit Committee dismissed CBIZ CPAs and engaged Grassi for fiscal 2027, but the filing says CBIZ’s prior audit reports were not adverse, disclaimed, qualified, or modified. 〔0〕
The more important signal is that known control weaknesses remain in the story. PharmaCyte disclosed no disagreements or reportable events other than weaknesses involving insufficient segregation of duties and insufficient management review controls. That makes the change mildly concerning from a reporting-process standpoint, but not evidence in this filing of a restatement, audit qualification, or accounting-policy dispute.
It barely changes the core business situation. Grassi’s first review will cover the quarter ending October 31, 2026, but the filing adds no update on the FDA hold, clinical progress, funding, or the underlying therapy program. The company’s latest quarterly filing still described the development program as delayed by the hold and related strategic issues.
Bottom line: This is a governance and reporting-process change, not a development breakthrough or setback. The absence of an audit dispute is reassuring, but the unresolved internal-control weaknesses keep the signal mixed and modest in importance.
Grassi’s first interim review for the quarter ending October 31, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!